title: World Antibody Drug Conjugate Summit Europe: February 21-23, 2011; Frankfurt, Germany.
abstract: The World Antibody Drug Conjugate Summit Europe, organized by Biorbis/ Hanson Wade was held in Frankfurt, Germany on February 21-23, 2011. Antibody drug conjugates (ADCs), also called immunoconjugates, are becoming an increasingly important class of therapeutics as demonstrated by the attendance of nearly 100 delegates at this highly focused meeting. Updates on three ADCs that are in late-stage clinical development, trastuzumab emtansine (T-DM1), brentuximab vedotin (SGN-35) and inotuzumab ozogamicin (CMC-544), were presented by speakers from ImmunoGen, Genentech, Roche, Seattle Genetics and Pfizer. These ADCs have shown encouraging therapeutic effects against solid tumors (T-DM1) and hematological malignancies (SGN-35, CMC-544). The key feature of the new generation of ADCs is the effective combination of the cytotoxicity of natural or synthetic highly potent antineoplastic agents, tumor selective monoclonal antibodies and blood-stable optimized linkers. Early clinical data for ADCs were showcased by Progenics Pharmaceuticals (PSMA ADC), Celldex (CDX-011) and Biotest (BT-062). Takeda, MedImmune and sanofi-aventis outlined their strategies for process development and analytical characterization. In addition, presentations on duocarmycin based-ADCs, alpha emitting immunoconjugates and antibody-conjugated nanoparticles were given by representatives from Syntarga, Algeta and the University of Stuttgart, respectively.
authors.affiliation: Centre d'Immunologie Pierre Fabre, Saint-Julien-en-Genevois, France. alain.beck@pierre-fabre.com
authors.forename: Alain
authors.initials: A
authors.lastname: Beck
authors.forename: Peter
authors.initials: P
authors.lastname: Senter
authors.forename: Ravi
authors.initials: R
authors.lastname: Chari
mesh_terms: D000080044:Ado-Trastuzumab Emtansine; D000911:Antibodies, Monoclonal / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001709:Biotechnology / Q000639:trends; D000079963:Brentuximab Vedotin; D002986:Clinical Trials as Topic; D006801:Humans; D018796:Immunoconjugates / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D007167:Immunotherapy / Q000639:trends*; D000080045:Inotuzumab Ozogamicin; D008453:Maytansine / Q000031:analogs & derivatives / Q000737:chemistry / Q000276:immunology / Q000627:therapeutic use; D009369:Neoplasms / Q000628:therapy*; D000068878:Trastuzumab
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000970:Antineoplastic Agents; D018796:Immunoconjugates; D008453:Maytansine; D000079963:Brentuximab Vedotin; D000068878:Trastuzumab; D000080045:Inotuzumab Ozogamicin; D000080044:Ado-Trastuzumab Emtansine